Oncology

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

Pirtobrutinib’s indication was expanded for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, allowing for treatment in earlier lines of therapy.

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

A cohort study of over 6 million US veterans revealed a 76% increased risk of pancreatic cancer following chronic hepatitis C infection.

The blood test helps patients avoid unnecessary and invasive biopsies.

Sam Klempner, MD, discusses early findings for the bispecific T-cell engager ASP2138, including monotherapy response, combination activity, and safety enhancements through subcutaneous dosing.

Long-term follow-up data showed that about 50% of patients achieved the trial's primary end point.

Expanding lung cancer screening to an age-based model significantly enhances early detection, potentially saving over 26,000 lives annually in the US.

Research funding disruptions at the National Institutes of Health (NIH) impact clinical trials, threatening treatment options for patients and highlighting the critical role of pharmacists in care continuity.

High-dose busulfan-melphalan enhances VRd therapy, improving progression-free survival in high-risk multiple myeloma patients undergoing ASCT.

CAR T-cell therapy shows promise for treating HER2-positive breast cancer with CNS metastases, offering a novel approach to improve patient outcomes.

The FDA approved durvalumab with FLOT chemotherapy, revolutionizing treatment for early gastric and gastroesophageal junction cancers, enhancing survival rates.

The combination has the potential to redefine the standard of care for a population that previously had limited therapeutic avenues.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

Advanced IHC assays enhance HER2-low breast cancer detection, improving treatment eligibility for trastuzumab deruxtecan.

The biosimilars can be used to treat osteoporosis and cancer-related bone loss in certain populations.

The approval is based on results from the phase 3 DeLLphi-304 clinical trial.

FDA approves daratumumab and hyaluronidase for treating newly diagnosed light chain (AL) amyloidosis, enhancing survival rates and treatment efficacy.

The FDA accelerates approval of sevabertinib for advanced non–small cell lung cancer, showcasing promising efficacy and manageable safety in clinical trials.

Routine multicancer early detection tests significantly improve early cancer diagnoses, reducing late-stage cases and enhancing treatment outcomes.

Epcoritamab-bysp demonstrated impressive response rates and improved progression-free survival.

Neladalkib offers durable responses and reduced side effects in TKI-pretreated patients.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Danny Rischin, MD, reviews findings from the C-POST trial.